EV Biologics Launches Excyte with $100 million Valuation

Stock Information for Asterias Biotherapeutics Inc. Common Series A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Asterias Biotherapeutics Inc. Common Series A

EV Biologics Updates on Funding and Sales
EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
EV Biologics Appoints Senior Investment Banker as Corporate Finance Director
EV Biologics Hires Senior Chief Financial Officer
EV Biologics Signs Exclusive Distribution Agreement for South America
EV Biologics Generates Mesenchymal Stem Cell Lines
EV Biologics Updates on Excyte Subsidiary Funding
EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.